Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of LY3361237 in adults with moderately to severely active systemic lupus erythematosus
2021-001406-30Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing LY3361237 450 mg every 2 weeks with Placebo every 2 weeks (2 arms). Primary endpoint: Arthritis and/or rash remission at Week 24. Started Jan 2022; status: terminated.
02
Drugs
venanprubart
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-001406-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001406-30.